Can cabozantinib enter the brain? Efficacy and research data analysis on patients with brain metastasis

Cabozantinib (Cabozantinib) is an oral small molecule targeted drug mainly used to treat various tumors such as renal cell carcinoma, hepatocellular carcinoma and thyroid cancer. It inhibits tumor angiogenesis and tumor cell proliferation by inhibiting multiple receptor tyrosine kinases, including MET, VEGFR2, AXL, etc. Cabozantinib can pass the blood-brain barrier and therefore may have some efficacy in patients with brain metastases. Some clinical studies in recent years have shown that cabozantinib has a relatively positive therapeutic effect in cancer patients with brain metastases, especially in certain types of tumors.

First, the pharmacological properties of cabozantinib give it a certain ability to penetrate the blood-brain barrier. Through studying the molecular properties of the drug and analyzing clinical data, the researchers found that cabozantinib can cross the blood-brain barrier to a certain extent and reach brain tissue. This makes it a potential treatment option for brain metastatic cancer. Especially in patients with metastatic tumors such as lung cancer and renal cancer, cabozantinib can effectively act on brain metastases, thereby slowing down disease progression.

In clinical studies, the efficacy of cabozantinib in tumor patients with brain metastases has been initially verified. For example, treatment with cabozantinib has shown partial responses and disease stabilization in patients with brain metastases such as non-small cell lung cancer and renal cancer. Especially in patients with non-small cell lung cancer, cabozantinib improves the tumor microenvironment and slows the growth of brain metastases by inhibiting the VEGF signaling pathway. Studies have shown that some patients have reduced or stabilized brain metastases after receiving cabozantinib treatment.

However, despite its certain efficacy, the efficacy of cabozantinib against brain metastases is still affected by multiple factors. Clinical studies have pointed out that not all patients with brain metastases can benefit from cabozantinib, and its efficacy may be affected by many factors such as tumor type, location of metastases, and the patient's overall health status. In addition, the therapeutic response of patients with brain metastases is also closely related to factors such as cerebral vascular permeability and tumor immune microenvironment. Therefore, the use of cabozantinib still needs to be cautious in these patients, and individualized treatment options are crucial.

Reference:https://en.wikipedia.org/wiki/Cabozantinib